Optimisation Tracks Sample Clauses

Optimisation Tracks. Attempt to utilise full potential of x86 instruction set Early in the hotspot analysis, the compiler was only capable of vectorizing small chunks of the code. About 99% of the executable and with it the computationally extensive regions were composed out of serial instructions. As the computationally most expensive region, the focus is set on the blockwiseBulkCollideAndStream() function in blockLattice3D.hh. It is responsible of advancing the fluid according to the Lattice Boltzmann Method. The rather complex nature of the 6 nested for loops made it necessary to traverse the call stack down to where the actual computations are performed. In the following, the subroutines addNaiveForce() and addGuoForce(), which are implemented in externalForceTemplateeD.h are investigated. Within these functions, the force with respect to each neighbouring cell is computed. The computations differ slightly, depending for instance on the distance of the centre points of the respective cells. To enable vectorisation or fused multiply-add (FMA) operations, we need to unify these computations and even more importantly, the data on the random-access memory (RAM) must be aligned. In principle, we archived this by introducing an additional buffer which stored precomputed results which had to computed individually and once this was done, vector operations were performed on the buffer. static T A[27] = {…} attribute ((aligned(64))); static T B[27] = {…} attribute ((aligned(64))); for(unsigned int i = 0; i < 9; ++i){ #ifdef _USE_BLAS C[i] = blas_ddot(3, &(A[i*3]), 1, &(B[i*3]), 1); #else C[i] = A[I*3] * B[i*3] + A[i*3 + 1] * B[i*3 +1] + A[i*3+2] * B[i*3+2] ; #endif } //some more computations to get to the final result for array f[] Throughout multiple test, the structure was altered to obtain more performance. For instance, instated of statically allocated buffers, a memory bool was used. Also, as shown in the sample code, XXXX level one routines were put in place. However, this technique did not lead to the desired decrease in execution time. Unfortunately, the way the 6 nested loops operate, results in rather short loops. Thus, the vector length is very limited. The benefits of using SIMD instructions were at best about even with the effort to prepare and align the data at each iteration. Additionally, the BLAS routines couldn’t show their full potential, due to the short vector length. Eventually, the idea to vectorise computations within a loop iteration had to be abandoned. How...
AutoNDA by SimpleDocs

Related to Optimisation Tracks

  • Access Toll Connecting Trunk Group Architecture 9.2.1 If CBB chooses to subtend a Verizon access Tandem, CBB’s NPA/NXX must be assigned by CBB to subtend the same Verizon access Tandem that a Verizon NPA/NXX serving the same Rate Center Area subtends as identified in the LERG.

  • Loop Provisioning Involving Integrated Digital Loop Carriers 2.6.1 Where InterGlobe has requested an Unbundled Loop and BellSouth uses IDLC systems to provide the local service to the End User and BellSouth has a suitable alternate facility available, BellSouth will make such alternative facilities available to InterGlobe. If a suitable alternative facility is not available, then to the extent it is technically feasible, BellSouth will implement one of the following alternative arrangements for InterGlobe (e.g. hairpinning):

  • Synchronisation Commissioning and Commercial Operation 8.1 The Developer shall provide at least forty (40) days advanced preliminary written notice and at least twenty (20) days advanced final written notice to ESCOM of the date on which it intends to synchronize the Power Project to the Grid System.

  • Directory Assistance messages; 6.1.1.4 IntraLATA Toll;

  • Loop Provisioning Involving IDLC 2.16.1 Where TWTC has requested an Unbundled Loop and AT&T uses IDLC systems to provide the local service to the customer and AT&T has a suitable alternate facility available, AT&T will make such alternative facilities available to TWTC. If a suitable alternative facility is not available, then to the extent it is technically feasible, AT&T will implement one of the following alternative arrangements for TWTC (e.g., hairpinning):

  • Interoperability To the extent required by applicable law, Cisco shall provide You with the interface information needed to achieve interoperability between the Software and another independently created program. Cisco will provide this interface information at Your written request after you pay Cisco’s licensing fees (if any). You will keep this information in strict confidence and strictly follow any applicable terms and conditions upon which Cisco makes such information available.

  • Purchase Order Flip via Ariba Network (AN) The online process allows suppliers to submit invoices via the AN for catalog and non- catalog goods and services. Contractors have the ability to create an invoice directly from their Inbox in their AN account by simply “flipping” the purchase order into an invoice. This option does not require any special software or technical capabilities. For the purposes of this section, the Contractor warrants and represents that it is authorized and empowered to and hereby grants the State and the third-party provider of MFMP the right and license to use, reproduce, transmit, distribute, and publicly display within the system the information outlined above. In addition, the Contractor warrants and represents that it is authorized and empowered to and hereby grants the State and the third-party provider the right and license to reproduce and display within the system the Contractor’s trademarks, system marks, logos, trade dress, or other branding designation that identifies the products made available by the Contractor under the Contract.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Construction Progress Meetings The Design Professional shall attend Construction Progress Meetings periodically held by the Contractor at the Site on a schedule determined by the Contractor. The Design Professional shall review the minutes of the meeting and provide his written comments to the minutes to the Owner and Contractor within seven calendar days after receipt of the meeting minutes.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!